Study for the mechanism of different biological agents interfering with psoriatic immune network and its correlation with clinical efficacy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900028507

Enrollment

Unknown

Registered

2019-12-24

Start date

2020-01-01

Completion date

Unknown

Last updated

2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Case series:Different biological agents

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with clinically diagnosed psoriasis and treated with biological agents; age and gender are not limited; can communicate with the prescribing physician through the smartphone-side login management platform; Voluntarily participate in the study, can follow the follow-up and participate in the long-term management of psoriasis , agree to take pre- and post-treatment peripheral blood samples and sign informed consent.

Exclusion criteria

Exclusion criteria: Those with latent tuberculosis, hepatitis B, and cancer history, those who failed to use biologic agents for screening.

Design outcomes

Primary

Measure	Time frame
IFN-gama, TNF-alpha, IL-12, IL-17A, 17F, IL-22, IL-23, IL-10 levels;	—

Countries

China

Contacts

Public ContactHou Suchun

The University of Hong Kong-Shenzhen Hospital

housc@hku-szh.org+86 18307555134

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026